Company's New Smartlipo MPX 46 Watts Enables Physicians to Melt and Remove Larger Areas of Fat 50% Faster, with Superior Patient Safety
WESTFORD, Mass., May 13 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today introduced the multi-wavelength Smartlipo MPX 46 watts, the latest and most powerful advance in the company's acclaimed Smartlipo platform of minimally invasive workstations for LaserBodySculpting.
The 46-watt workstation enables a physician to liquefy and remove larger areas of unwanted fat in about half the time required by the original 32-watt Smartlipo MPX. Like the original Smartlipo MPX, the 46-watt workstation is equipped with ThermaGuide, the latest in Cynosure's proprietary SmartSense family of intelligent energy delivery systems. ThermaGuide is designed to work in harmony with the laser. It continually monitors the temperature under the skin, and controls the output of energy, helping to ensure that the treatment area remains within a safe and an optimal temperature range for fat removal and tissue tightening through tissue coagulation. Cynosure has received U.S. Food and Drug Administration clearance to market the Smartlipo MPX. The company launched its 46-watt workstation at the recent American Society for Aesthetic Plastic Surgery's 42nd Annual Meeting.
"In my experience, no other laser-assisted lipolysis technology approaches the quality, safety or effectiveness of Cynosure's 46-watt Smartlipo MPX," said John W. Decorato, M.D., a board certified plastic surgeon in Staten Island, NY. "The nearly 50 percent increase in power allows me to treat larger areas, and multiple areas, with a faster response. Smartlipo MPX also is the only lipolysis technology on the market equipped with temperature sensing and control, a layer of safety that is unmatched in the industry."
"With the introduction of Smartlipo MPX 46 watts, we believe that we have strengthened the competitive advantage of our laser lipolysis technology not only from the standpoint of efficacy, but also in terms of patient safety," said Cynosure President and Chief Executive Officer Michael Davin.
Laser-assisted lipolysis with Smartlipo MPX is performed under local anesthesia, allowing a patient to go home the same day as the procedure is performed. "Compared with liposuction, the return to normal activities is much faster following a Smartlipo MPX procedure," Dr. Decorato said. "With Smartlipo MPX, the laser actually liquefies the fat, allowing it to be easily aspirated, as opposed to the vigorous mechanical suction of fat involved with liposuction, which can cause significant swelling and soft tissue trauma."
John Milllard, M.D., a board certified plastic surgeon based in Denver, said he was able to aspirate approximately 1200 mL of fat, the equivalent of roughly 5 cups, in 10 minutes with the 46-watt Smartlipo MPX. "I would never be able to obtain this amount this quickly and with such little effort using suction-assisted lipoplasty alone," he said. "The 46-watt MultiPlex makes it possible to perform procedures faster. Smartlipo MPX has enabled me to add two entirely new patient demographics to my practice: thinner patients and patients with areas of elastosis that typically could not be treated with traditional liposuction methods."
Smartlipo MPX uses Cynosure's patented MultiPlex technology to combine the benefits of the 1064-nm and 1320-nm wavelengths in one laser output. MultiPlex technology enables the workstation's two wavelengths to be fired sequentially, creating a blended thermal and photomechanical effect that efficiently liquefies fat and tightens skin through collagen remodeling. The two wavelengths can also be used individually, and each offers unique characteristics. The 30-watt 1064-nm wavelength disrupts a broad region of tissue while heating the treated areas evenly. The 1064-nm wavelength also mediates blood vessel coagulation enhancing hemostasis. The 16-watt 1320-nm wavelength is highly concentrated with minimal scatter, and is rapidly absorbed by the water in the tissue, which makes it highly effective in the disruption of fat and treatment of skin.
Research presented at the 2009 American Society for Laser Medicine and Surgery Annual Conference demonstrates with statistical significance that Smartlipo MPX tightens skin and shrinks skin tissue more efficaciously than skin treated with liposuction alone.
"Clinical research played a key role in the development of this technology," Davin said. "Prior to increasing the power of the system, we conducted extensive clinical studies to identify an optimal temperature threshold at which laser energy would effectively emulsify fat cells and tighten tissue. We developed an array of intelligent motion and temperature sensing technologies that automatically govern the flow of energy and prevent the system from exceeding temperature thresholds. These are tangible and fundamental innovations that we believe distinguish our laser lipolysis technology and reflect our commitment to the highest degree of patient care."
About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966, or visit www.cynosure.com.
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about expectations for its new Smartlipo MPX 46 watts as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the global economic recession and its effects on the aesthetic laser industry, Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
Contact: Scott Solomon Vice President Sharon Merrill Associates, Inc. 617-542-5300 firstname.lastname@example.org
|SOURCE Cynosure, Inc.|
Copyright©2009 PR Newswire.
All rights reserved